In a win for the rare disease space, the U.S. FDA granted accelerated approval for Rocket Pharmaceuticals Inc.’s Kresladi (marnetegragene autotemcel) as the first gene...

Multispecifics took center stage at this year’s ESMO TAT, emerging as one of the hottest trends in oncology research. Unlike traditional small-molecule drugs or monoclonal...

Biopharma deal value reached $61.17 billion in the first two months of 2026, roughly a 60% increase from the $38.11 billion logged in the same period of 2025 and marking...

Excalipoint Therapeutics Inc. launched with an oversubscribed $68.7 million seed financing round to advance a portfolio of T-cell engagers for solid tumors, marking one of...